Coagulation Factor IX for Hemophilia B Therapy

被引：27
作者：
Orlova, N. A. [1 ,2 ]
Kovnir, S. V. [1 ,2 ]
Vorobiev, I. I. [1 ,2 ]
Gabibov, A. G. [1 ]
机构：
[1] Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[2] Minist Healthcare & Social Dev Russian Federat, Hematol Res Ctr, Moscow 125167, Russia
来源：
ACTA NATURAE | 2012年 / 4卷 / 02期
关键词：
coagulation factor IX; hemophilia B; heterologous protein expression systems; CLOTTING FACTOR-IX; RECOMBINANT FACTOR-IX; SUSTAINED PHENOTYPIC CORRECTION; PREVIOUSLY TREATED PATIENTS; MEDIATED GENE-TRANSFER; LONG-TERM CORRECTION; HUMAN PROTEIN-C; FACTOR-X; PHARMACOKINETIC PROPERTIES; STRUCTURAL-ANALYSIS;
D O I：
10.32607/20758251-2012-4-2-62-73
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires constant protein replacement therapy. Reviewed herein are the current state in the manufacturing of FIX, improved variants of the recombinant protein for therapy, transgenic organisms for obtaining FIX, and the advances in the gene therapy of hemophilia B.
引用
收藏
页码：62 / 73
页数：12
相关论文
共 50 条
[41]   MYOCARDIAL-INFARCTION AFTER FEIBA THERAPY IN A HEMOPHILIA-B PATIENT WITH A FACTOR-IX INHIBITOR [J].
MIZON, P ;
GOUDEMAND, J ;
JUDE, B ;
MAREY, A .
ANNALS OF HEMATOLOGY, 1992, 64 (06) :309-311
[42]   The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate [J].
Chuansumrit, Ampaiwan ;
Moonsup, Yingwan ;
Sirachainan, Nongnuch ;
Benjaponpitak, Suwat ;
Suebsangad, Atchara ;
Wongwerawattanakoon, Pakawan .
BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (03) :208-211
[43]   Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B [J].
Geoffrey L Rogers ;
Ashley T Martino ;
Irene Zolotukhin ;
Hildegund CJ Ertl ;
Roland W Herzog .
Journal of Translational Medicine, 12
[44]   Mutant Macaque Factor IX T262A: A Tool for Hemophilia B Gene Therapy Studies in Macaques [J].
Ishiwata, Akira ;
Mimuro, Jun ;
Mizukami, Hiroaki ;
Kashiwakura, Yuji ;
Yasumoto, Atsushi ;
Sakata, Asuka ;
Ohmori, Tsukasa ;
Madoiwa, Seiji ;
Ono, Fumiko ;
Shima, Midori ;
Yoshioka, Akira ;
Ozawa, Keiya ;
Sakata, Yoichi .
THROMBOSIS RESEARCH, 2010, 125 (06) :533-537
[45]   Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis [J].
Shapiro, Amy D. ;
Chambost, Herve ;
Ozelo, Margareth C. ;
Falk, Aletta ;
Ahlin, Helena ;
Casiano, Sandra ;
Santagostino, Elena .
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (06)
[46]   Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B [J].
Wojciechowski, Jessica ;
Gaitonde, Puneet ;
Hughes, Jim H. ;
Ravva, Patanjali .
CLINICAL PHARMACOKINETICS, 2025,
[47]   Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII Deficiency [J].
Nichols, Timothy C. ;
Dillow, Aaron M. ;
Franck, Helen W. G. ;
Merricks, Elizabeth P. ;
Raymer, Robin A. ;
Bellinger, Dwight A. ;
Arruda, Valder R. ;
High, Katherine A. .
ILAR JOURNAL, 2009, 50 (02) :144-167
[48]   Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B [J].
Ducore, Jonathan M. ;
Miguelino, Maricel G. ;
Powell, Jerry S. .
EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) :559-571
[49]   Recombinant Factor IX for Clinical and Research Use [J].
Monahan, Paul E. ;
Di Paola, Jorge .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2010, 36 (05) :498-509
[50]   Molecular analysis of factor IX gene in an Iranian female with severe hemophilia B [J].
Karimipoor, Morteza ;
Kokabee, Leila ;
Kamali, Esmat ;
Karizi, Shohreh Zare ;
Zeinali, Sirous .
ACTA HAEMATOLOGICA, 2008, 119 (03) :151-153
12345